^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Solid Tumor

    Related cancers:
    1d
    APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (clinicaltrials.gov)
    P2, N=60, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Apr 2028 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1d
    MEDINDUCTION: Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=14, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=36 --> 14 | Unknown status --> Terminated; Toxicities due to the treatment, stop of enrollment
    Enrollment change • Trial termination
    |
    cisplatin • Imfinzi (durvalumab) • docetaxel • 5-fluorouracil
    1d
    LUCENT-GC-01: Eucine-Restricted Diet in Gastric Cancer Patients (clinicaltrials.gov)
    P1, N=37, Enrolling by invitation, Qilu Hospital of Shandong University
    New P1 trial
    1d
    Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC (clinicaltrials.gov)
    P2, N=26, Recruiting, Diwakar Davar | Trial completion date: Dec 2030 --> Dec 2036 | Trial primary completion date: Dec 2030 --> Dec 2036
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    1d
    A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer (clinicaltrials.gov)
    P=N/A, N=172, Not yet recruiting, Guangdong Provincial People's Hospital | N=114 --> 172 | Trial completion date: Oct 2027 --> Mar 2027
    Enrollment change • Trial completion date
    1d
    IMAHTEP: Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study (clinicaltrials.gov)
    P=N/A, N=11, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=20 --> 11 | Unknown status --> Terminated; Lack of inclusion
    Enrollment change • Trial termination
    1d
    Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (clinicaltrials.gov)
    P2, N=28, Recruiting, The Methodist Hospital Research Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Valcyte (valganciclovir)
    1d
    Reiki-Brachy: Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies (clinicaltrials.gov)
    P2, N=68, Recruiting, University of Utah | Trial primary completion date: Feb 2026 --> Jun 2026
    Trial primary completion date
    1d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Dec 2031 --> Nov 2036 | Trial primary completion date: Dec 2031 --> Nov 2036
    Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    1d
    Neuroblastoma Precision Trial (clinicaltrials.gov)
    P=N/A, N=93, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    1d
    Optimizing Functional Recovery After Breast Cancer Treatment (clinicaltrials.gov)
    P=N/A, N=352, Not yet recruiting, MGH Institute of Health Professions
    New trial
    1d
    ResQ108B-PANC: Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, ImmunityBio, Inc.
    New P1 trial
    |
    gemcitabine • albumin-bound paclitaxel • Anktiva (nogapendekin alfa inbakicept-pmln) • sotevtamab (AB-16B5) • zabinostat (CXD101)